血清糖基化纤连蛋白与血管生成因子预测慢性高血压孕妇叠加子痫前期
前瞻性研究纳入104例24–41周慢性高血压单胎孕妇,比较糖基化纤连蛋白、胎盘生长因子及sFlt-1/PlGF比值对2周内叠加子痫前期的预测效能,三种方法在约11%筛查阳性率下检出率仅约23–27%,预测效能均较差。
要点
- 糖基化纤连蛋白为无需实验室的即时检测,10分钟内出结果,可能替代现有血管生成标志物。
- 三种标志物对2周内叠加子痫前期的检出率仅约23–27%,预测效能差。
- 作者认为糖基化纤连蛋白与血管生成因子均不太可能改善慢性高血压孕妇的管理。
核心结论
- 糖基化纤连蛋白是简单的即时检测,无需实验室且10分钟内出结果,可能替代目前用于预测高危孕妇即将发生子痫前期的血管生成标志物;但糖基化纤连蛋白与血管生成因子对叠加子痫前期的预测效能均较差,不太可能改善慢性高血压孕妇的管理。
研究设计与样本
- 前瞻性研究,纳入104例24–41周慢性高血压单胎孕妇,采样时中位孕周34.1周(四分位距31.5–35.6周),84.6%(88/104)在<36周采样。
诊断标准与关键数值
- 在约10%固定筛查阳性率下比较预测效能,实际筛查阳性率11%、假阳性率约5%,三种方法对2周内叠加子痫前期的检出率相似,约为23–27%。
临床应用与阅片要点
- 糖基化纤连蛋白为即时检测,无需实验室,10分钟内出结果;但三种标志物对叠加子痫前期的预测效能均差,作者认为不太可能改善慢性高血压孕妇的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the predictive performance for delivery with pre-eclampsia (PE) within 2 weeks of assessment in women with chronic hypertension at 24-41 weeks' gestation between serum glycosylated fibronectin (GlyFn) concentration, serum placental growth factor (PlGF) concentration and soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF concentration ratio.
METHODS: This was a prospective study of 104 women with a singleton pregnancy and chronic hypertension presenting at 24-41 weeks' gestation. Twenty-six (25.0%) cases developed superimposed PE within 2 weeks of sampling. We compared the predictive performance for superimposed PE between GlyFn, PlGF and the sFlt-1/PlGF ratio at a fixed screen-positive rate of approximately 10%.
RESULTS: The median gestational age at sampling was 34.1 (interquartile range, 31.5-35.6) weeks and 84.6% (88/104) of cases were sampled at < 36 weeks. The predictive performance for superimposed PE of the three methods of screening was similar, with detection rates of about 23-27%, at a screen-positive rate of 11% and a false-positive rate of about 5%.
CONCLUSIONS: Measurement of GlyFn is a simple point-of-care test that can be carried out without need for a laboratory and provide results within 10 min of testing. In this respect, it could potentially replace the angiogenic markers that are used currently in the prediction of imminent PE in high-risk women. However, neither GlyFn nor angiogenic factors are likely to improve the management of women with chronic hypertension because their predictive performance for superimposed PE is poor. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Sokratous N, Bednorz M, Syngelaki A, et al. Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre-eclampsia in women with chronic hypertension. Ultrasound Obstet Gynecol. 2023. PMID: 37675881. doi:10.1002/uog.27475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。